lundi 21 septembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 8, 2026

Earnings week ahead: F, KO, CSCO, SHOP, MCD, BP, AMAT, COIN, MRNA, ROKU, and more

View original at seekingalpha.com
Earnings week ahead: F, KO, CSCO, SHOP, MCD, BP, AMAT, COIN, MRNA, ROKU, and more [earnings chart] K-Paul/iStock via Getty Images Earnings season continues with another busy, market-moving week ahead, as companies across autos, consumer staples, technology, healthcare, energy, utilities, financials, REITs, and material…
Opening lines of the source · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Airbnb shares trade close to intrinsic value, leaving a limited margin of safety

    80% confidence
  • Cleveland-Cliffs has approximately 37% upside over a 12-24-month horizon

    80% confidence
  • Cleveland-Cliffs interest burden is expected to exceed $600M this year

    80% confidence
  • Despite soft demand, elevated steel prices, and a challenging cost environment, Cleveland-Cliffs stands out as the only U.S. steel producer capable of meaningful balance-sheet and structural transformation

    80% confidence
  • CSCO blends cyclical and secular strengths for high-single-digit sales and low-teens EPS growth at under 20x P/E versus peers

    80% confidence
  • Moderna's preliminary 2025 outlook points to approximately $1.9B in revenue against $5.0B-$5.2B in GAAP operating expenses

    80% confidence
  • Moderna's updated five-year Phase 2b results for intismeran autogene showed a 49% reduction in death or recurrence in melanoma, with potential Phase 3 melanoma and Phase 2 renal cell carcinoma readouts possible in 2026

    80% confidence
  • Cisco will achieve 50-100bps annual EBIT expansion

    80% confidence
  • Cisco will achieve $3B FY26 AI revenue with >$4B orders from hyperscalers on Silicon One/P200 ramps, and 25%+ optics growth

    80% confidence
  • Ford is a classic cyclical stock where upside is capped at current levels and more attractive risk/reward emerges only below $10.50, given pressured margins and constrained earnings leverage

    80% confidence
  • Moderna is transitioning from pandemic-driven revenue toward cost discipline and pipeline execution, with breakeven targeted around 2028

    80% confidence
  • Without strategic action, CLF could post a ~$1.3B net loss in 2025, even with supportive steel pricing

    80% confidence
  • Cisco has 14.2% upside potential with $85.9 price target based on 6-7% annual growth from AI infrastructure demand, campus networking upgrades, and network security expansion

    80% confidence
  • Campus networking will see 6-8% industry growth through 2026 via WiFi 7, PoE, and legacy EOL/EOS

    80% confidence

Data points we hold from this source

Ford Motor Company · revenue41.78 billion_USD
Ford Motor Company · vehicle sales2200000 units

Cité dans ces articles de Via News

Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Notre lecture des données ›
Signaux que nous suivons
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Tendances que nous surveillons ›
Là où les sources divergent
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
Nous signalons les conflits ouvertement ›
Vérifié récemment
Vérifié avec la source d'origine
4,982
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,982 faits vérifiés avec la source5,299 documents sources archivés
Interrogez ces données → isubstrate.com